The largest and longest study of the obesity drug Wegovy has shown people maintain significant weight loss for at least four years, with fewer serious adverse events than those given placebo ...
Anti-obesity jabs could reduce the risk of heart attacks, strokes or heart failure in obese people regardless of the amount of weight they lose while on the drug, researchers have found.
The largest and longest study of the obesity drug Wegovy has shown people maintain significant weight loss for at least four years, with fewer serious adverse events than those given placebo 'dummy' ...
A large, long-term trial of the weight-loss medication Wegovy (semaglutide) found that people tended to lose weight over the first 65 weeks on the drug—about one year and three months—but then ...
Adults who were overweight or had obesity and took Wegovy (semaglutide) lost an average of 10 percent of their body weight — and kept it off — after four years on the drug. Semaglutide may ...
In a recent study published in the journal Nature Medicine, an international team of researchers evaluated the effects of semaglutide on weight and anthropometric outcomes, as well as safety and ...